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BVITAMINS, INCLUDINGB6 AND FO-late (B9), as well as related en-zymes in the1-carbonpathway,are essential for DNA synthesis
and methylation. The 1-carbon metabo-
lismprocessiscomplexandinvolvesmul-
tiple interactionsbetweenBvitamins,ho-
mocysteine, and methionine, which in
turn are required for generation of
S-adenosylmethionine,anessentialcom-
ponent of methylation reactions.1 Defi-
ciencies in B vitamins may increase the
probability of DNA damage and subse-
quentgenemutations,andmayinfluence
geneexpressionviaaberrantmethylation
patterns.2 Given their involvement in
maintaining DNA integrity and gene ex-
pression,thesenutrientshaveapotentially
importantrole ininhibitingcancerdevel-
opment,andoffer thepossibilityofmodi-
fyingcancerriskthroughdietarychanges.
Majorsourcesof1-carbonnutrientsand
related vitamins are varied and include
fruits andgreen leafyvegetables (folate),
fortifiedcerealsandwholegrains (B6), as
well as meat and dairy products (B12).3,4
B vitamin levels are also likely to be in-
fluencedbygeneticvariantsandotherfac-
tors includingalcoholconsumptionand
low-grade inflammation.5-9 Although
many countries have initiated folic acid
supplementationof flourandother food-
types, deficiencies in nutrient levels of B
vitamins have been shown to be high in
many western populations.10
Untilnow, themainfocusofstudiesof
Bvitaminsandcancerpreventionhasbeen
onfolateandcolorectal cancer.Tworan-
domized trialsof folate supplementation
investigated whether it may prevent co-
lorectaladenomasamonghigh-riskpopu-
lations, but failed to identify a protective
effect.11,12Althoughrandomizedtrialsmay
restrict confounding from other expo-
sures, they have limitations in assessing
the role of specific nutrients because (1)
they are limited in size and the number
ofcancers thatoccur in the follow-uppe-
riod; (2)supplementationis randomized
over a relatively short period (several
years); and (3) they are unrelated to life-
long vitamin levels prior to the study.
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Context B vitamins and factors related to 1-carbonmetabolism help tomaintain DNA
integrity and regulate gene expression and may affect cancer risk.
Objective To investigate if 1-carbon metabolism factors are associated with onset
of lung cancer.
Design, Setting, andParticipants TheEuropeanProspective Investigation intoCan-
cer and Nutrition (EPIC) recruited 519978 participants from 10 countries between 1992
and 2000, of whom 385747 donated blood. By 2006, 899 lung cancer cases were iden-
tifiedand1770controlparticipantswere individuallymatchedbycountry, sex,dateofbirth,
and date of blood collection. Serum levels were measured for 6 factors of 1-carbon me-
tabolism and cotinine.
Main OutcomeMeasure Odds ratios (ORs) of lung cancer by serum levels of 4 B
vitamins (B2, B6, folate [B9], and B12), methionine, and homocysteine.
Results Within theentire EPICcohort, theage-standardized incidence ratesof lungcan-
cer (standardized to the world population, aged 35-79 years) were 6.6, 44.9, and 156.1
per100000person-yearsamongnever, former,andcurrent smokers formen, respectively.
Thecorrespondingincidenceratesforwomenwere7.1,23.9,and100.9per100000person-
years, respectively.After accounting for smoking, a lower risk for lung cancerwas seen for
elevated serum levels of B6 (fourth vs first quartileOR, 0.44; 95%confidence interval [CI],
0.33-0.60; P for trend.000001), aswell as for serummethionine (fourth vs first quartile
OR, 0.52; 95%CI, 0.39-0.69; P for trend.000001). Similar and consistent decreases in
riskwere observed in never, former, and current smokers, indicating that results were not
due to confounding by smoking. Themagnitude of riskwas also constantwith increasing
lengthof follow-up, indicatingthat theassociationswerenotexplainedbypreclinicaldisease.
A lower riskwas also seen for serumfolate (fourth vs first quartileOR,0.68; 95%CI, 0.51-
0.90;P for trend =.001), although thiswas apparentonly for former andcurrent smokers.
When participants were classified by median levels of serum methionine and B6, having
above-median levelsofbothwasassociatedwitha lower lungcancer riskoverall (OR,0.41;
95% CI, 0.31-0.54), as well as separately among never (OR, 0.36; 95% CI, 0.18-0.72),
former (OR,0.51;95%CI,0.34-0.76),andcurrentsmokers (OR,0.42;95%CI,0.27-0.65).
Conclusion Serum levels of vitamin B6 andmethionine were inversely associatedwith
risk of lung cancer.
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Alternatively, largepopulationcohorts
with baseline blood collection can com-
pare vitamin serum levels with subse-
quentcancerdevelopment in largenum-
bers. Validity of the results depends on
several assumptions regarding the mea-
surementofsingleserummarkersatbase-
lineincludingthattheyare(1)representa-
tiveofpast exposures, (2)notassociated
with underlying preclinical disease, and
(3) not explained by other causes of the
diseasesuchassmoking.Apotential role
of B6 in lung cancer has been reported
from a randomized trial of-tocopherol
and beta carotene (the ATBC study) in
29 000malesmokers inFinland.13 Inter-
pretation of this study is difficult due to
the limited sample size, the absence of
never smokers, and the possibility that
smoking may suppress B6 levels.
Wethereforeconductedacomprehen-
sive investigation of B vitamins and me-
thionine status based on serum samples
fromthetheEuropeanProspectiveInves-
tigationintoCancerandNutrition(EPIC)
cohort study, a large population cohort
of more than 500 000 adults conducted
in 10 European countries.
METHODS
Study Cohort
EPICrecruitmentprocedures,collection
of questionnaire data, anthropometric
measurements, and blood samples have
been described in detail elsewhere.14 In
brief, standardizedquestionnairedataon
dietaryandnondietaryvariableswerecol-
lected between 1992 and 2000 from
519 978 individuals across Europe, of
whom385 747providedabloodsample.
The present study included individuals
diagnosed with lung cancer after blood
collection inthecasegroupandmatched
participants in the control group from 8
of the10participatingcountries:France,
Italy, Spain, United Kingdom, the Neth-
erlands, Greece, Germany, and Sweden
(excluding the Malmö center).
A blood sample was collected accord-
ing to a standardized protocol. Filled sy-
ringeswerekeptat5°Cto10°C,protected
fromlight,andtransferredtoa local labo-
ratory for furtherprocessing.Blood frac-
tions(serum,citrateplasma,redcells,and
buffy coat) were aliquoted into 0.5-mL
strawsthatweresubsequentlyheatsealed
andstored in liquidnitrogen tanksat the
InternationalAgencyforResearchonCan-
cer(IARC),Lyon,France,at−196°C,ex-
cept in Umea˚, Sweden, where samples
were stored in 1.8-mL plastic tubes in
−80°C freezers.
Follow-up for Cancer Incidence
InItaly, theNetherlands,Spain,Sweden,
and Great Britain, incident cancer cases
were identified through record linkage
with regional or national cancer regis-
tries. In France, Germany, and Greece,
follow-up was based on a combination
of methods, including health insurance
records, cancerandpathologyregistries,
and active follow-up through study par-
ticipants and their next of kin. For each
EPIC study center, closure dates of the
study period were defined as the latest
datesofcomplete follow-upforbothcan-
cer incidence and vital status (dates var-
ied between centers, December 2002-
December 2005). Vital status follow-up
was more than 98% complete.
Selection of Case and
Control Group Participants
Among the 519 978 EPIC participants,
2206werediagnosedwith incident lung
cancerbytheendof the follow-upperiod
forallcenters.Individualswhodidnotdo-
nate a blood sample, had missing infor-
mationon thedateofblooddonation,or
had a history of another cancer (except
nonmelanomaskincancer)at thetimeof
blooddonationwereexcluded(n=614),
leaving1592caseparticipants.After fur-
therexclusionsofNorway(n=15),Den-
mark (n=473), and the Malmö center in
Sweden(n=202),serumsamples(plasma
inUmea˚)wereavailable for899casepar-
ticipants(3didnothaveserumavailable).
Dataonhistologywerecollectedfromeach
centerwherepossible.Lungcancercases
were defined on the basis of the Interna-
tionalClassificationofDiseases forOncol-
ogy, Second Edition, and included all in-
vasive cancers that were coded as C34.
Foreachcaseparticipant,2controlpar-
ticipantswerechosenatrandomfromap-
propriaterisksetsconsistingofallcohort
members alive and cancer free (except
nonmelanomaskincancer)at thetimeof
diagnosisof the indexcase.Matchingcri-
teriawerecountry, sex,dateofbloodcol-
lection(±1month, relaxed to±5months
for sets without available controls), and
dateofbirth (±1year, relaxed to±5years
for setswithoutavailablecontrolpartici-
pants). Two control participants were
available for 873 in the case group, and
1controlparticipantwasavailable for24
in the case group, resulting in a matched
sample sizeof897caseand1770control
participants.Nocontrolparticipantswere
availablefor2inthecasegroup,andafur-
ther47controlparticipantswereincluded
from1center(Umea˚)withoutamatched
caseparticipant.These49controlpartici-
pants do not contribute to subsequent
overall matched analyses, although they
were retained in thedata set andcontrib-
ute to unmatched stratified analysis. All
participants gave written informed con-
sent toparticipate inthestudyandthere-
search was approved by the local ethics
committees intheparticipatingcountries
andthe IARCinstitutional reviewboard.
Biochemical Analyses
Allbiochemicalanalyseswereperformed
at Bevital A/S (http://www.bevital.no),
Bergen, Norway. The study included
measurements of serum concentrations
(plasma from Umea˚) of B2 (riboflavin),
B6 (measured as pyridoxal 5-phos-
phate, its active form), folate (B9), B12 (co-
balamin), total homocysteine, and me-
thionine. All case participants and all but
2 control participants were successfully
analyzed. Along with pyridoxal 5-
phosphate, 2 other forms of B6 were mea-
sured: pyridoxal, which is converted into
pyridoxal 5-phosphate, and pyridoxic
acid, the catabolite of pyridoxal 5-
phosphate that is excreted in the urine.
We also measured cotinine as an indica-
tor of recent smoking behavior. Concen-
trations of B2, B6, homocysteine, meth-
ionine, and cotinine were determined by
mass spectrometry–based methods (liq-
uid chromatography coupled to tandem
mass spectrometry; gas chromatogra-
phy coupled to tandem mass spectro-
metry),1 5 , 1 6 and microbiological
methods were used to determine concen-
trations of folate (Lactobacillus casei)17,18
and B12 (Lactobacillus leichmannii).19
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Sampleswereanalyzedinbatchesof86
andqualitycontrol included6calibration
samples, 2 control samples, and 1 blank
sample ineachbatch. Samples fromcase
and control participants were kept at
−80°Candanalyzedinrandomorder.All
staff intheBevital laboratorywereblinded
to the case-control status of the blood
samples.
Statistical Analyses
Age-standardized incidence rates per
100 000 person-years of lung cancer for
the complete EPIC cohort of 519 978
individuals were calculated separately
by sex and smoking status, and stan-
dardized to the world population aged
35 through 79 years.20
Overall riskanalysesof lungcancer in-
volvedcalculatingquartilesofserumlev-
els for each of the 4 B vitamins, as well as
methionineandhomocysteine,basedon
the distribution among control partici-
pants.Theoddsratio(OR)and95%con-
fidenceinterval(CI)oflungcancerforpar-
ticipants in the second, third, and fourth
quartilewascalculatedrelativetothefirst
quartileusingconditional logisticregres-
sion,conditioningonindividualcasesets.
Additionaladjustmentwasconducted
for quartiles of cotinine level, which was
considered to be the most accurate mea-
sure of smoking intensity at the time of
bloodcollection.Includingfurthersmok-
ing variables (smoking status, duration
ofsmoking,averagecigarettessmokedper
day)didnotalter theresultsnotably.Ad-
ditional adjustment was also conducted
for body mass index (BMI [calculated as
weight inkilogramsdividedbyheight in
meterssquared]),educationalattainment,
and alcohol consumption at the time of
recruitment.Analyseswerealsoconducted
afterstratifyingfornever,former,andcur-
rentsmokersusingunconditional logistic
regressionadjustingforageatrecruitment,
sex, country, and in current smokers,
quartiles of cotinine levels. The overall
trendforeachanalyte(P fortrend),aswell
as stratifiedanalyses,wereconductedby
including the base 2 logarithm (log2) of
the analyte concentrations as a continu-
ous variable in a separate logistic regres-
sion model. The OR trend estimate from
thismodelmaybeinterpretedas therela-
tiveriskassociatedwithadoublingincon-
centrations.Allanalyseswerealsorepeated
afterremovingcaseparticipantsdiagnosed
within 1 year of blood collection.
Prespecified stratified analyses were
conducted forcountry,histology, smok-
ing status (including time since quitting
among former smokers), sex, time from
blood draw to diagnosis, as well as edu-
cationalattainmentandalcohol intakeat
recruitment. We used 2 tests to exam-
ineheterogeneityinORinstratifiedanaly-
ses.Dietary intakeofmajor foodgroups,
as well as B2, B6, and B12, were available
as assessed by the EPIC food frequency
questionnaires in each center. The asso-
ciation between lifestyle and dietary fac-
tors with serum levels were investigated
usinglinearregressionmodels,adjusting
forcase-controlstatus,age,sex,andcoun-
try,andfurtheradjustedforcotininewhen
appropriate (in quartiles).
Cumulative risks of lung cancer were
calculated up to the age of 79 years by
estimating cumulative rates (the sum of
age-specific incidence rates by sex and
smoking status in 5-year categories) and
applying a standard formula to convert
these to cumulative risks.20 These risks
do not take into account competing
causes of death. Similarly, cumulative
risks by 1-carbon exposure categories
were calculated by applying OR esti-
mates and control exposure distribu-
tions on the cumulative rates.21 These
were calculated separately for men and
women, and for never, former, and cur-
rent smokers.
All P values were 2-sided and statis-
tical analyses were conducted using SAS
version 9.2 (Cary, North Carolina).
RESULTS
Incidence Rates of Lung Cancer
Within the EPIC Cohort
WithintheentireEPICcohortof519 978
individuals, the age-standardized inci-
dence ratesof lungcancer (standardized
totheworldpopulationaged35-79years)
were for men 6.6, 44.9, and 156.1 per
100 000 person-years among never,
former,andcurrentsmokers,respectively.
The corresponding incidence rates for
women were 7.1, 23.9, and 100.9 per
100 000 person-years, respectively.
Baseline Characteristics of Case
and Control Participants
Amongthe899caseand1815controlpar-
ticipants within the nested case-control
study,11%ofcaseparticipantswerenever
smokers and 29% were former smokers
atthetimeofrecruitment,comparedwith
39%and37%ofcontrolparticipants, re-
spectively (TABLE 1). Among both case
and control participants, 62% were men
and their median age at blood draw was
59 years (95% range, 43-73 years). The
mediantimebetweenblooddrawanddi-
agnosisoflungcanceramongthecasepar-
ticipantswas62months(Table1).Serum
levelsofB2,B6, folate,B12,andmethionine
were similar between never and former
smokers,althoughlowerincurrentsmok-
ers (eTable 1 available at http://www
.jama.com). Similarly, smoking intensity
among current smokers (assessed by co-
tinine) was inversely associated with fo-
late, B12, and B6.
Serum Levels of B Vitamins
and Lung Cancer Risk
Case and control participants were sub-
sequentlycomparedforquartilesofserum
levels of each of the four B vitamins, as
well as homocysteine and methionine
(TABLE 2). After adjusting for matching
variablesandcotinine,asubstantial lower
riskforlungcancerwasseenforincreasing
levels of B6 (fourth vs first quartile OR,
0.44; 95% CI, 0.33-0.60; P for trend
.000001).Alowerriskwasalsoseenfor
increasing methionine (fourth vs first
quartile OR, 0.52; 95% CI, 0.39-0.69; P
fortrend.000001).Moderatedecreases
in risk were seen for the second quartile
ofbothB6 andmethionine(secondvsfirst
quartileOR,0.78[95%CI,0.60-1.01]and
0.88 [95% CI, 0.69-1.15], respectively),
as well as for the third quartile (third vs
firstquartileOR,0.53[95%CI,0.40-0.71]
and 0.49 [95% CI, 0.36-0.65], respec-
tively).Adjustmentbyadditionalvariables
including BMI, educational attainment,
andalcoholconsumptiondidnotmodify
the results (Table 2), and neither did si-
multaneous adjustment of each analyte
(Table2).Excludingcaseparticipantswho
werediagnosedwithin1yearafterblood
draw also provided very similar results
(eTable 2).
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After stratifying by smoking status,
similar and consistent decreases in risk
wereobservedforneversmokers, former
smokers, and current smokers for both
B6 andmethionine, indicatingthatresults
werenotdue toasmoking-associatedar-
tifact(Table2).Forexample,amongnever
smokers,P for trend was .004 for B6, and
Pfortrendwas.04formethionine.Amod-
erate lowerriskwasobservedfor increas-
ingserumfolatelevels(fourthvsfirstquar-
tile OR, 0.68; 95% CI, 0.51-0.90; P for
trend =.001), although this association
wasrestrictedtoformerandcurrentsmok-
ers, andwasnotapparent inneversmok-
ers(fourthvs firstquartileOR,0.84;95%
CI, 0.43-1.65; P for trend=.41). No sig-
nificanttrendsinriskwereobservedover-
all forserumvitaminB2 (P fortrend=.11),
B12 (P fortrend=.06),orhomocysteine(P
for trend=.78).Regarding theadditional
measures of serum vitamin B6 that were
available,asimilarlowerriskwasobserved
forpyridoxal (fourthvs firstquartileOR,
0.51; 95% CI, 0.38-0.69; P for trend
.0009),althoughnot forpyridoxicacid
(fourthvs firstquartileOR,0.83;95%CI,
0.60-1.14;Pfortrend=.30).Simultaneous
adjustment for B6 (as measured by pyri-
doxal5-phosphate),pyridoxal,andpyri-
doxic acid resulted in an unchanged es-
timate for B6 (fourth vs first quartile OR,
0.43;95%CI,0.28-0.66)andnoassocia-
tion for pyridoxal and pydidoxic acid.
Weexploredfurther theassociationof
allBvitaminsandmetabolitesafterstrati-
fying on various effect modifiers and es-
timating the OR for log2 of serum levels.
ThisOR(ORlog2)maybeinterpretedasthe
relative risk associated with a doubling
of the exposure level. ORlog2 for B6 over-
all was 0.74 (95% CI, 0.66-0.83; P for
trend=310−7; eFigure 1). This result
was consistent when stratified by poten-
tial effect modifiers including country,
histology, smoking status, and time from
blood draw to diagnosis. Similarly, the
ORlog2 for methionine overall was 0.51
(95%CI,0.39-0.67;P for trend=410−6)
and was not modified after stratifica-
tion by potential effect modifiers
(eFigure 2). Additional stratified analy-
ses were conducted for B2, folate, B12, and
homocysteine, and no apparent effect
modification was observed (eFigure 3,
Table 1. Baseline and Clinical Characteristics of Study Participants
Discrete Variables
No. (%) of Participants in Group
Case (n = 899) Control (n = 1815)
Participating countries
Great Britain 176 (20) 356 (20)
Germany 161 (18) 319 (18)
Italy 139 (15) 278 (15)
Spain 130 (14) 259 (14)
The Netherlands 121 (13) 242 (13)
Greece 90 (10) 186 (10)
Sweden 58 (6) 127 (7)
France 24 (3) 48 (3)
Sex
Men 559 (62) 1126 (62)
Women 340 (38) 689 (38)
Smoking status
Never smokers 96 (11) 707 (39)
Former smokers 260 (29) 663 (37)
Years since quitting 10 132 (52) 179 (28)
Years since quitting 10 120 (48) 462 (72)
Current smokers 529 (59) 413 (23)
Unknown 14 (2) 32 (2)
Education
Primary school 460 (53) 787 (45)
Technical/professional school 193 (22) 386 (22)
Secondary school 110 (13) 241 (14)
Higher educationa 97 (11) 320 (18)
Body mass indexb
20 40 (4) 42 (2)
20-25 348 (39) 586 (32)
25-30 383 (43) 873 (48)
30-35 105 (12) 261 (14)
35 23 (3) 53 (3)
Alcohol intake at recruitment
Never drinkers 34 (4) 88 (5)
Former drinkers 90 (10) 122 (7)
5 g/d 268 (30) 574 (32)
5-20 g/d 200 (22) 541 (30)
20 g/d 307 (34) 490 (27)
Continuous variables, median (5th-95th percentile)
Age at blood draw, y 59 (43-73) 59 (43-73)
Serum levels for components of the 1-carbon metabolism
Vitamin B2, Riboflavin, nmol/L 17.1 (7.1-61.3) 19.7 (8.1-71.8)
Vitamin B6, Pyridoxal 5-phosphate, nmol/L 31.6 (13.2-87.9) 40.3 (16.9-116)
Folate, nmol/L 12.2 (5.3-32.5) 14.4 (6.6-38.8)
Vitamin B12, cobalamin, pmol/L 350 (180-629) 343 (190-607)
Homocysteine, µmol/L 12.6 (8.1-23.3) 12.1 (8.0-20.4)
Methionine, µmol/L 27.4 (19.0-42.6) 29.2 (20.9-43.8)
Clinical characteristics, case participants only
Age at diagnosis, median (range), y 64 (38-85)
Months from blood draw to diagnosis, median (range) 62 (1-151)
Distribution of months from blood draw to diagnosis, No. (%)
1-35 232 (26)
36-59 202 (22)
60-83 223 (25)
84-151 242 (27)
Histology, No. (%)
Small cell carcinoma 110 (12)
Adenocarcinoma 272 (30)
Large cell carcinoma 50 (6)
Squamous cell carcinoma 200 (22)
Other carcinoma 267 (30)
SI conversion factors: To convert B2 to µg/dL, divide by 26.6; B6 to ng/mL, divide by 4.046; folate to ng/mL, divide by
2.266; B12 to pg/mL, divide by 0.7378; and methionine, divide by 67.02.
a Indicates completion. Higher education includes a university degree.
bBody mass index is calculated as weight in kilograms divided by height in meters squared.
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eFigure 4, eFigure 5, eFigure 6). The
lower risk for folate (ORlog2=0.80; 95%
CI, 0.71-0.90) was mainly restricted
to former smokers (ORlog2=0.78; 95% CI,
0.64-0.95) and current smokers
(ORlog2=0.76; 95% CI, 0.63-0.92).
We further investigated the associa-
tion of having a high level of B6, meth-
ionine, or both by classifying individu-
als based on whether they were above
or below the median values of these
markers as measured among control
participants (defined as 40.3nmol/L
forB6 and29.2µmol/L formethionine
[FIGURE1]). There were above-median
values for both markers in 27% of con-
trolparticipantscomparedwithonly14%
of case participants (OR, 0.41; 95% CI,
0.31-0.54). Intermediate risks were ob-
tained for participants who had low me-
thionine but high B6 levels (OR, 0.58;
95%CI,0.45-0.75), aswell as thosewho
had high methionine and low B6 levels
(OR,0.56;95%CI,0.44-0.71).Theover-
all trend for having high levels of none,
1, or both measures was significant (P
for trend=310−12). When stratifying
bysmoking, similar results forbothhigh
B6 andmethioninewereobservedamong
never (OR, 0.36; 95% CI, 0.18-0.72),
former (OR, 0.51; 95% CI, 0.34-0.76),
andcurrent smokers (OR,0.42;95%CI,
0.27-0.65). When case and control par-
ticipants were further classified accord-
ing to the median level of folate in con-
trol participants (14.4 nmol/L), having
above-median levels for all 3 vitamins
resulted in an OR of 0.32 (95% CI, 0.23-
0.45; eFigure 7).
Table 2. Odds Ratios of Lung Cancer for Serum Levels of Vitamins B2, B6, Folate, B12, Homocysteine, and Methionine
Quartile (Range)
Case/Control
Participantsa
Odds Ratio (95% Confidence Interval)
Model 1b
(n = 897/1768)c
Model 2d
(n = 853/1621)c
Model 3e
(n = 892/1748)c
Never Smokersf
(n = 96/707)g
Former
Smokersf
(n = 260/663)g
Current
Smokersf,h
(n = 529/413)g
Vitamin B2, riboflavin, nmol/L
1 (2.9-13.3) 284/452 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
2 (13.4-19.7) 237/451 0.92 (0.71-1.21) 0.90 (0.68-1.18) 1.03 (0.77-1.36) 1.06 (0.53-2.14) 0.87 (0.57-1.35) 0.77 (0.54-1.09)
3 (19.8-29.9) 185/450 0.83 (0.62-1.11) 0.85 (0.63-1.13) 0.98 (0.72-1.32) 1.14 (0.58-2.23) 0.80 (0.51-1.25) 0.80 (0.53-1.23)
4 (30.0-1433) 188/452 0.82 (0.61-1.09) 0.85 (0.63-1.14) 0.99 (0.73-1.35) 0.96 (0.48-1.91) 0.94 (0.60-1.46) 0.91 (0.58-1.43)
P for trendi .11 .22 .81 .38 .66 .46
Vitamin B6, pyridoxal 5-phosphate, nmol/L
1 (5.7-28.4) 380/452 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
2 (28.5-40.3) 231/451 0.78 (0.60-1.01) 0.76 (0.57-1.00) 0.83 (0.63-1.10) 0.76 (0.41-1.40) 0.78 (0.52-1.18) 0.68 (0.47-0.97)
3 (40.4-57.7) 152/450 0.53 (0.40-0.71) 0.54 (0.40-0.73) 0.59 (0.43-0.80) 0.57 (0.30-1.09) 0.51 (0.33-0.80) 0.64 (0.42-0.98)
4 (57.8-629) 131/452 0.44 (0.33-0.60) 0.43 (0.32-0.59) 0.50 (0.36-0.69) 0.37 (0.17-0.77) 0.50 (0.32-0.77) 0.67 (0.42-1.06)
P for trendi 2  10−7 5  10−7 2  10−5 .004 .006 .04
Folate, nmol/L
1 (0.1-10) 326/452 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
2 (10.1-14.4) 221/455 0.84 (0.64-1.10) 0.87 (0.66-1.15) 0.85 (0.64-1.12) 1.23 (0.64-2.36) 0.68 (0.44-1.05) 0.92 (0.64-1.32)
3 (14.5-22.4) 193/452 0.78 (0.59-1.03) 0.80 (0.60-1.07) 0.81 (0.60-1.10) 0.90 (0.47-1.75) 0.75 (0.49-1.15) 0.84 (0.56-1.26)
4 (22.5-395) 159/455 0.68 (0.51-0.90) 0.68 (0.50-0.91) 0.69 (0.50-0.95) 0.84 (0.43-1.65) 0.58 (0.37-0.91) 0.54 (0.34-0.83)
P for trendi .001 .002 .008 .41 .02 .003
Vitamin B12, cobalamin, pmol/L
1 (28.7-274) 227/453 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
2 (275-343) 199/454 0.94 (0.72-1.25) 0.97 (0.73-1.29) 0.95 (0.71-1.26) 1.00 (0.50-1.99) 0.86 (0.57-1.31) 0.92 (0.61-1.38)
3 (344-427) 240/454 1.29 (0.99-1.70) 1.33 (1.01-1.76) 1.32 (0.99-1.75) 0.78 (0.40-1.51) 1.26 (0.83-1.90) 1.49 (1.00-2.24)
4 (428-3800) 233/454 1.22 (0.92-1.62) 1.20 (0.90-1.59) 1.35 (1.00-1.82) 0.80 (0.41-1.54) 1.39 (0.92-2.11) 1.29 (0.84-1.98)
P for trendi .06 .08 .04 .37 .05 .05
Homocysteine, µmol/L
1 (4.9-10.3) 202/450 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
2 (10.4-12.1) 197/452 0.83 (0.62-1.12) 0.79 (0.59-1.06) 0.81 (0.60-1.10) 0.73 (0.41-1.31) 0.80 (0.50-1.27) 1.11 (0.71-1.74)
3 (12.2-14.5) 227/451 0.85 (0.63-1.15) 0.84 (0.62-1.15) 0.73 (0.53-1.01) 0.62 (0.32-1.19) 0.78 (0.49-1.24) 1.00 (0.64-1.57)
4 (14.6-139) 270/452 0.87 (0.64-1.17) 0.82 (0.60-1.12) 0.76 (0.54-1.07) 0.42 (0.19-0.90) 0.92 (0.58-1.46) 1.05 (0.67-1.66)
P for trendi .78 .84 .62 .03 .71 .38
Methionine, µmol/L
1 (11-25.3) 309/451 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
2 (25.4-29.1) 250/451 0.88 (0.68-1.15) 0.90 (0.69-1.18) 0.91 (0.69-1.18) 1.30 (0.73-2.30) 0.69 (0.46-1.03) 1.25 (0.84-1.87)
3 (29.2-33.9) 176/451 0.49 (0.36-0.65) 0.51 (0.38-0.69) 0.51 (0.38-0.69) 0.79 (0.41-1.52) 0.71 (0.46-1.10) 0.55 (0.36-0.81)
4 (34.0-69.2) 161/452 0.52 (0.39-0.69) 0.53 (0.40-0.72) 0.54 (0.40-0.73) 0.48 (0.22-1.04) 0.57 (0.37-0.88) 0.66 (0.43-1.01)
P for trendi 3  10−7 2  10−6 5  10−6 .04 .005 .02
SI conversion factors: To convert B2 to µg/dL, divide by 26.6; B6 to ng/mL, divide by 4.046; folate to ng/mL, divide by 2.266; B12 to pg/mL, divide by 0.7378; and methionine, divide by 67.02.
aNumbers include all case and control participants for whom laboratory measurements were available, including those participants from uninformative case sets excluded from conditional
analyses.
bAssessed by conditional logistic regression conditioning on individual case set adjusting for cotinine (in quartiles).
cNumbers (n=case/control participants) only include participants from informative case sets, ie, those from case sets with at least 1 case and 1 control participant.
dFurther adjusted for body mass index (in quartiles), educational attainment (in 5 groups), and alcohol intake at recruitment (in quartiles).
eAdjusted for cotinine (in quartiles) and mutually adjusted for all the other analytes simultaneously (in quartiles).
fAssessed by unconditional logistic regression adjusting for age (in 5-year categories), country, and sex.
gNumbers (n=case/control participants) also include participants from uninformative case sets who were excluded from conditional analyses.
hFurther adjusted for cotinine (in quartiles).
iP for trend assessed by the base 2 logarithm of the serum levels.
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Dietary Intake of B Vitamins
and Lung Cancer Risk
Smokersconsumedfewer fruitsandveg-
etables thandidneverand former smok-
ers (eTable 3). There were weak corre-
lations between dietary vitamin measures
and serum levels for B2, B6, and B12
(eTable 4), consistent with observa-
tions in other studies.22-24 In the com-
parison between serum B6 and dietary B6
as assessed fromthe food frequencyques-
tionnaires among the same group of case
and control participants, while a decreas-
ing risk was observed with increasing lev-
els of serum B6, no association was
observed with dietary B6 either overall
(P for trend=.81), or among the second
(OR, 0.91), third (OR, 0.99), and fourth
quartile (OR, 1.02; eTable 5). A potential
increased risk was observed with increas-
ing levels of dietary B12 (P for trend
=.007) that mirrored the nonsignifi-
cant increase observed for serum B12 lev-
els (P for trend=.06). No association was
observed for dietary intake of B2, simi-
lar to the results for serum B2 concen-
trations.
Cumulative Risks of Lung Cancer
Using thesex, smoking,andage-specific
incidencerateswithinEPIC,weobtained
cumulative risks of lung cancer (by age
79 years in the absence of other causes
ofdeath)amongnever, former, andcur-
rent smokersof0.50%,3.4%,and10.8%
for men, and 0.47%, 1.6%, and 6.9% for
women, respectively. Cumulative risks
weresubsequentlycalculatedseparately
for participants with above-median and
below-median serum levels of both B6
andmethionine(FIGURE2).Amongcur-
rent smokers, cumulative risks ranged
from 14.9% for men with above-median
levels of both and 6.6% for men with
below-median levels of both. The
correspondingestimatesforwomenwere
8.9% and 3.8%, respectively. Cumula-
tive risks among former-smoking men
were 5.2% and 2.7%, respectively, and
2.5% and 1.3% among women, respec-
tively. Among never-smoking men, cu-
mulative risks were 0.90% and 0.32%,
respectively, and 0.75% and 0.27%
among women, respectively. Similar re-
sults were obtained for quartiles of B6,
folate, and methionine separately
(eTable 6).
COMMENT
Ourresultssuggestthatabove-medianse-
rummeasuresofbothB6 andmethionine,
assessedonaverage5yearspriortodisease
onset, are associated with a reduction of
at least50%ontheriskofdevelopinglung
cancer. An additional association for se-
rumlevelsoffolatewaspresent,thatwhen
combined with B6 and methionine, was
associatedwitha two-thirds lowerriskof
lung cancer.
Reverse Causation and
Confounding by Smoking
Anoncausalexplanationfortheobserved
results is thatof reversecausation, ie,un-
derlyingpreclinicaldiseaseissuppressing
serum levels of both B6 and methionine.
If this were the case, one would expect
greater associations in the initialperiods
after blood collection, when preclinical
diseasemightbemost apparent.TheOR
for both serum B6 and methionine were,
however, very stable over the 12-year
follow-up after blood collection, which
would seem to exclude any possible
reverse causation bias (eFigure 1;
eFigure 2). As a further check against any
possible reverse causation, we repeated
analysis after excluding participants who
developed lung cancer within 1 year of
blood collection. Overall results for B6 (P
for trend.000001) and methionine (P
for trend=.00001) were almost identical
to those including all cases (eTable 2).
Asecondpossiblenoncausal explana-
tion is that the results areconfoundedby
cigarettesmoking.Again,thereareanum-
ber of reasons why this does not appear
tobeaplausibleexplanationoftheresults.
First,whenwecomparedvariouslifestyle
exposures with serum levels among all
participants, current smoking appeared
tobeassociatedwithall serummeasures,
including those that were not subse-
quently associated with lung cancer
(eTable 1). The strongest associated mea-
sures among current smokers were se-
rum vitamin B6 (concentration ratio [CR]
compared with never smokers, 0.78;
P10−15), B2 (CR, 0.79;P10−11), homo-
cysteine (CR, 1.09; P=10−9), and folate
Figure 1. Odds Ratios of Lung Cancer for Groups of Serum Vitamin B6 and Methionine
Adjusted for Cotinine
Level
Vitamin B6 Methionine
No. of Participants
in Group
Case Control
P for
Trend
Overall
Low
Low
High
High
Low
High
Low
High
408
208
154
129
498
415
414
488
<.001
Never smokers
Low
Low
High
High
Low
High
Low
High
43
15
23
15
184
143
169
211
.002
Former smokers
Low
Low
High
High
Low
High
Low
High
95
58
51
56
165
132
177
189
.001
Current smokers
OR
(95% CI)
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]Low
Low
High
High
Low
High
Low
High
261
131
80
57
143
130
59
81
0.56 (0.44-0.71)
0.58 (0.45-0.75)
0.41 (0.31-0.54)
0.50 (0.26-0.96)
0.52 (0.29-0.93)
0.36 (0.18-0.72)
0.65 (0.42-1.01)
0.50 (0.33-0.76)
0.51 (0.34-0.76)
0.55 (0.39-0.78)
0.86 (0.55-1.34)
0.42 (0.27-0.65)
<.001
0.2 0.5 1.0 2.0
OR (95% CI)
High/low for vitamin B6 denotes levels above/below 29.2 nmol/L, high/low for methionine denotes serum levels
above/below 40.3 µmol/L. Odds ratios (ORs) were assessed by unconditional logistic regression adjusting for age
(in 5-year categories), country, sex, and cotinine (in quartiles); P for trendwas assessed by a discrete variable (0-2)
indicating if 1 or 2 of the analytes are high; the black squares and horizontal lines indicate the ORs and 95% con-
fidence intervals (CIs); the size of the black squares is proportional to the inverse variance of the logistic regression
estimates.
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(CR, 0.86; P10−6). Serum vitamin B12
measures were moderately suppressed
(CR, 0.94; P=.001), although the least-
affected measure was for methionine
(CR, 0.97;P=.01). Second, former smok-
ing did not appear to suppress any of the
6 serum measures, with average levels
being very similar between former and
never smokers (eg, CR=0.99 and 1.00
for B6 and methionine, respectively).
Fromthesedata,onemightconclude that
serum measures among former smok-
ers are not confounded by smoking sta-
tus, although serum measures among
current smokers are. Similarly, when
comparing dietary intake of major food
groups across smoking categories, no dif-
ferences between never and former
smokers were observed, whereas cur-
rent smokers consumed lower levels of
both fruits and vegetables (eTable 3).
Third, an association among never
smokers, as is apparent for both B6 and
methionine,wouldappeartoruleoutcon-
founding by smoking as an explanation
for the association with both. Smoking
cannot therefore explain the association
withneversmokers,andisunlikelytoex-
plaintheassociationamongformersmok-
ers. Among current smokers, some con-
foundingisplausible,althoughgiventhat
we have been able to adjust for cotinine,
themostparsimoniousexplanationwould
seem to be that the results among never,
former,andcurrentsmokersareroughly
equivalent.
Other Potential Confounders
An additional noncausal explanation is
that the observed associations are con-
founded by other risk factors for lung
cancer, including occupation or mark-
ers of social deprivation. Serum me-
thionine appeared to be unrelated to
most potential confounders for which
information in the EPIC cohort was
available including employment sta-
tus, physical activity, BMI, and alco-
hol consumption (eTable 1). There was
a small increase in serum methionine
with higher educational attainment
(CR, 1.01; P=.002), although any fur-
ther adjustment for this and BMI had
no material effect on the overall OR
(Table 2). Similarly, although base-
line levels of serum vitamin B6 were as-
sociated with educational attainment,
physical activity, and with alcohol con-
sumption, adjustment for these vari-
ables had no effect on the observed OR
(Table 2). Given the absence of any ap-
parent confounding effect from these
exposures, residual confounding from
poorly measured exposures would also
appear to be unlikely. This leaves the
possibility that other unidentified ex-
posures for lung cancer (eg, specific oc-
cupational exposures), are strongly
associated with both serum B6 and
methionine levels, and explain the ob-
served results. Given their joint corre-
lation was also limited ( = .17;
eTable 7), any unknown confounder of
these associations would have to be
strongly associated with both, as well
as with lung cancer. We would there-
fore argue that, having excluded smok-
ing, other potential confounders that
explain these associations are unlikely.
Independent and Combined
Associations of Serum B6,
Methionine, and Folate
SerummarkersofBvitaminsandrelated
metabolites have been assessed for mul-
tiple cancer sites in prospective cohorts,
includingcolorectal,25-30 gastric,31 pancre-
atic,32 prostate,33,34 andbreast cancer.35-37
Studiesofcolorectalcancerandserumvi-
taminB6 wouldseemtoprovideverycon-
sistent evidence of a protective associa-
tion in the order of 50% lower risk when
comparingthefourthquartilewiththefirst
quartileof theexposuredistribution.Our
results showing a lower risk of lung can-
cerwith increasingserumvitaminB6 sta-
tusarethereforeconsistentwithobserved
results fromother largecohortstudies for
colorectal cancer, although evidence is
limited for other cancer types. Previous
studies on colorectal and other cancers
have not investigated a potential role for
serum methionine levels, and to our
knowledge no previous studies have re-
portedonthecombinedassociationofse-
rum vitamin B6, folate, and methionine.
Theseepidemiologicalfindings,aswell
as results fromanimal studies,38 have led
totheconductof2largerandomizedstud-
ies aiming to test whether folate supple-
mentation reduces the risk of colorectal
cancer.11,12 Neither study provided any
positiveevidenceof a reducedriskof co-
lorectaladenomasamongparticipantsran-
domizedtoreceive folicacidsupplemen-
tation,withsomeevidenceintheUSstudy
of an increased risk of advanced or mul-
tipleadenomas.Theseresultshave led to
thehypothesisthattimingoffolatesupple-
mentation may be essential, with folate
beingbeneficial inprimarypreventionof
Figure 2. Cumulative Risks of Lung Cancer to Age 79 Years Among Never, Former, and
Current Smokers
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Cumulative risks up to age 79 were based on age-specific incidence rates estimated within the European Prospec-
tive Investigation intoCancerandNutrition (EPIC)cohort, separately formenandwomen,andamongnever, former,
and current smokers, combinedwith odds ratio estimates of lung cancer bymedian serum levels of B6 andmethio-
nine.High/high indicateshavingabove-median levelsofbothvitaminB6 andmethionineand low/low indicateshav-
ing below-median levels.
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colorectalneoplasia,butpotentiallyharm-
ful inthepresenceofestablishedcancer.39
Similarly, it isalsoplausiblethatanyeffect
withB6 andmethioninemaybemodified
by stage of disease.
Regression Dilution
OurserumBvitaminmeasurementswere
performed on a single blood sample ob-
tained at study recruitment and as such
are likely tobe imperfectestimatesofun-
derlyinghistoricalexposurelevel.Thecor-
relationbetweenourestimateandtheun-
derlyinglong-termlevelislikelytodepend
onanumberof factors includingday-to-
day, seasonal, andmore long-termvaria-
tion within an individual. The conse-
quence of this is that our estimated OR
will be weaker than the true underlying
association. It ispossible, if onehasmul-
tiplebloodsamplestakenpreferablymany
yearsapart, tocorrect for this“regression
dilution.”40 Asanindicationof theextent
to which our OR estimates might be at-
tenuated by regression dilution, we ac-
quiredrepeatmeasurements taken1year
apart for serum vitamin B6, methionine,
andfolatefromthecontrolgroup(n=755)
of the Western Norway B-vitamin Inter-
ventionTrial (WENBIT).41 This resulted
in corrected OR estimates for all 3 mea-
sures that were substantially lower than
uncorrectedmeasures,althoughparticu-
larly so for methionine (eTable 8). For
example, comparing the fourth and first
quartile of vitamin B6, the corrected OR
was 0.25 for vitamin B6, 0.47 for folate,
and 0.13 for methionine. Similar re-
sults were obtained for repeat measures
taken 1 month and 3 years apart
(eTable 8). Given that the combined OR
of having above-median levels of all 3
measures was 0.32 (eFigure 7), these re-
sults indicate that the true underlying as-
sociation is likely to be much stronger.
Comparison of Food Frequency
Questionnaires andSerumMeasures
We observed no association between vi-
tamin B6 estimated from the food fre-
quency questionnaires and lung cancer
risk, in contrast to the strong protective
association observed from serum levels
(eTable 5). There are at least 2 possible
interpretations for this discrepancy. One
is that serum measures are a far more ac-
curate reflection of vitamin B6 intake than
estimates based on multiple food types
determined by questionnaire. The cor-
relation of 0.16 between the food fre-
quency questionnaires and serum lev-
els, similar to that observed in other
studies,22-24 would be in line with this. An
alternative explanation is that serum lev-
els of vitamin B6 differ strongly be-
tween case and control participants not
because of intake but because of absorp-
tion,distribution,orcatabolismof thecir-
culatingnutrient.Thiswill result in lower
serum levels among the case partici-
pants even when intake is similar. An ad-
ditional consequence would be that di-
etary modification would not be a
suitable means for reducing cancer in-
cidence. Assuming the associations with
B6 are causal, identifying which of these
2 explanations is true will be crucial.
Public Health
DietarysourcesofB6arevariedandinclude
beans, grains, meats, poultry, fish, and
some fruits and vegetables, whereas pri-
marysourcesofmethionineare fromani-
malproteins,aswellassomenutsandveg-
etable seeds.3 Given that serum levels of
Bvitaminsandmetabolitesareatleastpar-
tially determined by diet (eTable 4), and
are clearly affected by vitamin supple-
ments,41 low vitamin levels are therefore
modifiable. However, based on the recent
experience of folate intervention trials for
colorectal adenomas, as well as past in-
tervention trials for lung cancer,11,12 it is
unlikely that further intervention trials
of B vitamins would be advisable. A re-
cent pooled analysis of 2 randomized
trials reported a potential excess in risk
for all cancers combined and lung cancer
among participants randomized to re-
ceive folic acid and B12, with no apparent
effect forB6.42 These results would further
support the hypothesis that randomiza-
tion to B vitamins over several years does
not provide any short-term benefits in
cancer reduction, although do not in-
form about potential protective effects re-
garding maintaining adequate serum lev-
els of B vitamins over the life course.43
If our observations regarding serum
methionine, B6, or both are shown to be
causal, identifying optimum levels for re-
ducing future cancer risk would appear
to be appropriate. It is also possible that
one may be able to obtain further evi-
dence of potential causal effects, at least
for B6, by analyzing modifier genes that
have recently been identified from ge-
nome-wide studies of vitamin B serum
levels.8 Given the modest effect on se-
rum levels associated with these gene
variants, very large sample sizes will be
required in order to obtain robust results.
Lung cancer remains the most com-
mon cause of cancer death in the world
today and is likely to remain so for the
near future.44 It is essential that for lung
cancer prevention, any additional evi-
dence about causality does not detract
from the importance of reducing the
numbers of individuals who smoke to-
bacco. With this in mind, it is important
to recognize that a large proportion of
lung cancer cases occur among former
smokers, making up the majority in
countrieswheretobaccocampaignshave
been particularly successful, and a non-
trivial number of lung cancer cases oc-
cur also among never smokers, particu-
larly among women in parts of Asia.45-47
Clarifying the role of B vitamins and re-
lated metabolites in lung cancer risk is
likelythereforetobeparticularlyrelevant
for former smokers and never smokers.
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